Menhycia (ACYW135 meningococcal conjugate vaccine (CRM197)) / CanSino - LARVOL DELTA

Clinical Study of the Safety of Menhycia in 3-Month-Old Infants (clinicaltrials.gov) - P4 | N=3011 | Completed | Sponsor: CanSino Biologics Inc. | Active, not recruiting ➔ Completed | Trial completion date: Dec 2025 ➔ May 2026 | Trial primary completion date: Dec 2025 ➔ Apr 2026

Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Infectious Disease

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years (clinicaltrials.gov) - P3 | N=1480 | Completed | Sponsor: CanSino Biologics Inc. | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Infectious Disease • Meningococcal Infections

Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate Vaccine (clinicaltrials.gov) - P1 | N=150 | Not yet recruiting | Sponsor: Sinovac Life Sciences Co., Ltd.

New P1 trial • CNS Disorders • Infectious Disease • Meningococcal Infections

Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants (clinicaltrials.gov) - P4 | N=3011 | Active, not recruiting | Sponsor: CanSino Biologics Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Apr 2025 ➔ Dec 2025 | Trial primary completion date: Apr 2025 ➔ Dec 2025

Enrollment closed • Trial completion date • Trial primary completion date • CNS Disorders • Infectious Disease

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years (clinicaltrials.gov) - P3 | N=1480 | Active, not recruiting | Sponsor: CanSino Biologics Inc. | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Jul 2024

Trial completion date • Trial primary completion date • CNS Disorders • Infectious Disease • Meningococcal Infections

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years (clinicaltrials.gov) - P3 | N=1480 | Active, not recruiting | Sponsor: CanSino Biologics Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Infectious Disease • Meningococcal Infections

Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants (clinicaltrials.gov) - P4 | N=3000 | Recruiting | Sponsor: CanSino Biologics Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Infectious Disease

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years (clinicaltrials.gov) - P3 | N=1480 | Recruiting | Sponsor: CanSino Biologics Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Infectious Disease • Meningococcal Infections

Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants (clinicaltrials.gov) - P4 | N=3000 | Not yet recruiting | Sponsor: CanSino Biologics Inc.

New P4 trial • CNS Disorders • Infectious Disease

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years (clinicaltrials.gov) - P3 | N=1480 | Not yet recruiting | Sponsor: CanSino Biologics Inc. | Initiation date: Dec 2023 ➔ Apr 2024

Trial initiation date • CNS Disorders • Infectious Disease • Meningococcal Infections